Compare
Insight Molecular Diagnostics Inc. vs Aspira Women's Health Inc. vs Volitionrx Ltd vs Celldex Therapeutics, Inc.
| Latest fiscal year | Insight Molecular Diagnostics Inc. IMDX | Aspira Women's Health Inc. AWHL | Volitionrx Ltd VNRX | Celldex Therapeutics, Inc. CLDX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.05M | $9.22M | $1.73M | $1.54M |
| Revenue growth (YoY) | +115.6% | +0.4% | +40.0% | -78.0% |
| Gross margin | 56.7% | 64.2% | n/a | 87.1% (computed) |
| Operating margin | n/m | -85.9% | n/m | n/m |
| Net margin | n/m | -138.7% | n/m | n/m |
| Net income | -$50.22M | -$12.78M | -$23.36M | -$258.76M |
| EPS (Diluted) | -$1.65 | -$0.37 | n/a | -$3.90 |
| Operating cash flow | -$22.18M | -$7.03M | -$19.68M | -$210.94M |
| Free cash flow | -$25.37M | -$7.04M | -$19.77M | -$213.66M |
| Cash & equivalents | $11.58M | $1.75M | $1.12M | $28.87M |
| Total assets | $25.76M | $5.46M | $6.90M | $582.98M |
| Total liabilities | $57.22M | $12.39M | $42.49M | $55.82M |
| Shareholders' equity | -$31.46M | -$6.93M | -$34.25M | $527.16M |
| Return on year-end equity | n/a | n/a | n/a | -49.1% |
| Shares outstanding | 28.68M | 43.48M | 125.78M | 66.55M |
Revenue, most recent five fiscal years
| Fiscal year | Insight Molecular Diagnostics Inc. | Aspira Women's Health Inc. | Volitionrx Ltd | Celldex Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $4.05M Ended 2025-12-31 | $9.22M Ended 2025-12-31 | $1.73M Ended 2025-12-31 | $1.54M Ended 2025-12-31 |
| 1 year earlier | $1.88M Ended 2024-12-31 | $9.18M Ended 2024-12-31 | $1.23M Ended 2024-12-31 | $7.02M Ended 2024-12-31 |
| 2 years earlier | $1.50M Ended 2023-12-31 | $9.15M Ended 2023-12-31 | $775.3K Ended 2023-12-31 | $6.88M Ended 2023-12-31 |
| 3 years earlier | $958.0K Ended 2022-12-31 | n/a | $306.4K Ended 2022-12-31 | $2.36M Ended 2022-12-31 |
| 4 years earlier | $2.20M Ended 2021-12-31 | n/a | $90.0K Ended 2021-12-31 | $4.65M Ended 2021-12-31 |